InDex Pharmaceuticals: News Regarding CONCLUDE Initiation
Redeye leaves a short comment on InDex Pharmaceuticals following yesterday evening's announcement that patient recruitment for the phase III study is planned to initiate after the summer. This is a minor delay, but it has a limited impact. We reiterate our Base case of SEK 4. 5 following the announcement.